Nuvectis

Nuvectis

Pharmaceutical Preparations

Company website
Foundation year

2020

Open date

2/2/2022

About

Total Funding 

$15,3M


Nuvectis Pharma is a bio-pharmaceutical company intended to develop novel targeted therapeutics for the treatment of cancer.

Nuvectis is led by a management team comprised of industry veterans with broad and extensive drug development experience, and a proven track record of clinical and regulatory success. By leveraging our core competencies of target selection, drug profiling, and clinical and regulatory execution we are building our pipeline of product candidates for development in various oncology indications.


Number of employees

5 - 10


Headquarters

New York, New York, US


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.